A subgroup of patients with ovarian cancer with simultaneous PI3KCA and MAPK mutations responded to PI3K/AKT/mTOR inhibitors, suggesting that not all patients demonstrate resistance when the MAPK pathway is concomitantly activated 20. This evidence concerns the gene MTOR and ovarian carcinoma.